PADCEV (enfortumab vedotin-ejfv)


Drug overview for PADCEV (enfortumab vedotin-ejfv):

Generic name: enfortumab vedotin-ejfv (en-FORT-ue-mab ve-DOE-tin)
Drug class: Antineoplastic Monoclonal Antibodies
Therapeutic class: Antineoplastics

Enfortumab vedotin, an anti-nectin-4 antibody conjugated with the microtubule inhibitor monomethyl auristatin E (MMAE), is an antineoplastic agent.

No enhanced Uses information available for this drug.
DRUG IMAGES
  • PADCEV 20 MG VIAL
    PADCEV 20 MG VIAL
  • PADCEV 30 MG VIAL
    PADCEV 30 MG VIAL
The following indications for PADCEV (enfortumab vedotin-ejfv) have been approved by the FDA:

Indications:
Transitional cell carcinoma of the urinary tract


Professional Synonyms:
Urothelial carcinoma